Whalen Wealth Management Inc. Makes New Investment in Insulet Co. (NASDAQ:PODD)

Whalen Wealth Management Inc. bought a new position in shares of Insulet Co. (NASDAQ:PODD) during the 4th quarter, HoldingsChannel reports. The firm bought 986 shares of the medical instruments supplier’s stock, valued at approximately $257,000.

Other institutional investors have also added to or reduced their stakes in the company. Marshall Wace LLP purchased a new position in Insulet during the second quarter valued at approximately $99,978,000. Baillie Gifford & Co. boosted its position in Insulet by 20.7% during the 3rd quarter. Baillie Gifford & Co. now owns 2,275,701 shares of the medical instruments supplier’s stock valued at $529,669,000 after acquiring an additional 389,639 shares in the last quarter. Mizuho Securities USA LLC increased its holdings in shares of Insulet by 5,928.1% in the 3rd quarter. Mizuho Securities USA LLC now owns 325,821 shares of the medical instruments supplier’s stock valued at $75,835,000 after acquiring an additional 320,416 shares during the period. Charles Schwab Investment Management Inc. raised its position in shares of Insulet by 43.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 636,265 shares of the medical instruments supplier’s stock worth $148,091,000 after acquiring an additional 193,839 shares in the last quarter. Finally, Westfield Capital Management Co. LP lifted its stake in shares of Insulet by 27.6% during the 3rd quarter. Westfield Capital Management Co. LP now owns 754,872 shares of the medical instruments supplier’s stock worth $175,697,000 after purchasing an additional 163,388 shares during the last quarter.

Analyst Ratings Changes

Several equities analysts have issued reports on PODD shares. JPMorgan Chase & Co. lifted their target price on Insulet from $280.00 to $330.00 and gave the company an “overweight” rating in a research note on Thursday, December 12th. Citigroup boosted their price objective on shares of Insulet from $283.00 to $310.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. Raymond James increased their target price on shares of Insulet from $213.00 to $260.00 and gave the company an “outperform” rating in a research report on Monday, October 14th. Canaccord Genuity Group upped their price target on Insulet from $269.00 to $304.00 and gave the stock a “buy” rating in a research report on Monday, December 9th. Finally, Barclays raised their price objective on Insulet from $220.00 to $234.00 and gave the stock an “equal weight” rating in a research report on Monday, November 11th. Three research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $272.81.

Insider Activity

In other Insulet news, EVP Eric Benjamin sold 12,394 shares of Insulet stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total value of $3,470,320.00. Following the completion of the transaction, the executive vice president now owns 11,383 shares of the company’s stock, valued at approximately $3,187,240. The trade was a 52.13 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Lauren Budden sold 915 shares of the stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $275.62, for a total transaction of $252,192.30. Following the sale, the chief accounting officer now directly owns 5,733 shares in the company, valued at approximately $1,580,129.46. The trade was a 13.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.47% of the company’s stock.

Insulet Stock Performance

PODD opened at $278.89 on Thursday. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. Insulet Co. has a 12-month low of $160.19 and a 12-month high of $282.86. The firm has a 50 day moving average of $266.52 and a two-hundred day moving average of $234.38. The firm has a market capitalization of $19.56 billion, a PE ratio of 47.76, a P/E/G ratio of 3.47 and a beta of 1.22.

Insulet (NASDAQ:PODD) last issued its earnings results on Thursday, November 7th. The medical instruments supplier reported $0.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.77 by $0.13. Insulet had a net margin of 21.22% and a return on equity of 27.98%. The firm had revenue of $543.90 million during the quarter, compared to analysts’ expectations of $518.50 million. During the same quarter last year, the company posted $0.71 earnings per share. On average, analysts anticipate that Insulet Co. will post 3.22 EPS for the current year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.